8 minute read
May 8, 2023

Linvencorvir: A Novel HBV Core Protein Allosteric Modulator from Roche


allosteric HBV modulator Ph. II for chronic hepatitis B (CHB) opt. of known allosteric heteroaryl pyrimidine core protein modulator J. Med. Chem., March 10, 2023 Roche, Shanghai, CN

Drug Hunter Team

A Ph. II liver-targeting HBV core protein modulator optimized for ADMET properties. Linvencorvir (RG7907), a novel HBV core protein allosteric modulator, offers a promising treatment option for chronic hepatitis B which affects 296 million people globally. It possesses an interesting glue-like mechanism that causes the HBV core protein to [...]



Other molecules you may be interested in